x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012814
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Rat |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly193 of human SCAP protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SCAP |
| UniProt No. | Q12770 |
| Gene ID | 22937 |
| Gene Description | SREBP cleavage activating protein is a membrane-bound protein essential in regulating sterol regulatory element binding protein processing. In cholesterol-starved cells, SREBPs move from the ER to the Golgi apparatus with the help of SCAP, where the precursor SREBPs are cleaved by site-1 and site-2 proteases. Released SREBP amino-terminal domains enter the nucleus and bind to sterol response elements located in the promoters of a number of genes responsible for the cholesterol synthesis. Research studies show that the SCAP/SREBP pathway is critical for diabetic fatty liver development and carbohydrate-induced hypertriglyceridemia in mice. In addition, the SCAP/SREBP pathway is required to protect cancer cells from lipotoxicity. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
